

## REMARKS

The specification has been amended to provide the chemical names for some trademarked products. Support is found in the attached website materials for Docetaxel, Bronopol, and VANTOCIL (Attachment A). These materials can be found at the following URLs:

<http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a696031.html>;

<http://www.chemindustry.com/chemicals/search/B/bronopol.html>;

<http://www.archbiocides.com/newproducts/vantocil/default.asp>.

Claims 33-34 have likewise been amended to refer to the chemical names. Typographical errors have been corrected.

Claims 56-60 have been added; these claims include no new matter. The shape of the scaffold is discussed, for example, at page 7, lines 5-7 and 14-15. The therapeutic agents are discussed, for example, at page 14, lines 4-17. Based on the present Amendment and the following Remarks, Applicants respectfully request that the Examiner reconsider and withdraw all outstanding rejections.

Claims 61-68 have been added; these claims include no new matter. Support regarding the coated scaffold may be found, for example, on pages 12-16 of the written description. Support regarding the therapeutic agent may be found, for example, at page 6, lines 9-13; page 12, lines 1-5; page 14, lines 4-6 and 11-17; page 15, line 11; page 16, line 1; page 20, the table following line 15; and page 21, lines 1-4. A metal scaffold is discussed, for example, at the following: page 7, lines 14-15 and 29-33; page 9, lines 20-23; page 10, lines 24-27; page 16, line 1; and page 21, lines 14-15. Loading of the therapeutic agent is discussed, for example, at page 5, lines 8-12.

Claims 25-42 have been amended to depend from claim 61, rather than from claim 23. Thus, the limitation of a loading of at least 100 micrograms per square centimeter of coating has been removed, and the limitation of the therapeutic agent comprising an antithrombogenic and/or an antiangiogenic agent in an effective amount has been added to claims 25-42. Claims 43, 45, and 50 have been amended to remove the limitation of a loading of therapeutic agent of at least about 100 micrograms per square centimeter, and dependent claims 69-71 including the limitation of a loading

of therapeutic agent of at least about 100 micrograms per square centimeter have been added.

**Rejections under 35 U.S.C. § 103 over U.S. Patent No. 6,110,483 to Whitbourne et al.**

Claims 23-25 and 28-52 stand rejected under 35 U.S.C. §103(a) as being unpatentable over U.S. Patent No. 6,110,483 to Whitbourne et al. (hereinafter '483), as indicated in item 3 on page 2 of the Office action of January 6, 2005.

The examiner concedes that '483 is "silent to the specific design of the substrates regarding their edges and surfaces" (Office action, item 4, page 3). Independent claim 23 of the instant application requires that "a scaffold compris[e] adjacent edges or surfaces in close proximity to each other". Because '483 does not teach the location and orientation of edges and surfaces, it does not teach or suggest the limitation of claim 23 of a scaffold comprising adjacent edges or surfaces in close proximity to each other.

Independent claim 23 of the instant application further recites "said coating ... bridging from one edge or surface to another..." In the written description of the instant application, an example is provided of a device in which the scaffold is a coil having open windings, with the coating "not only cover[ing] the surface of the wire, but also bridg[ing] from one winding to the next..." (instant application, page 7, lines 17-18). '483 does not teach the limitation of independent claim 23 of the instant application of bridging of the coating, but rather only teaches that the coating "forms a thin continuous layer over the substrate..." ('483, column 3, lines 17-18).

Claims 43, 45, and 50 similarly refer to "edges or surfaces in close proximity to each other..." and a formulation or coating bridging from one edge or surface to another. Thus, the '483 patent does not teach or suggest all the claim limitations of the independent claims 23, 43, 45, and 50, and thus does not teach or suggest all the limitations of the dependent claims. The examiner has not established a *prima facie* case of obviousness. In rejecting independent claims 23, 43, 45, and 50, and claims which depend from them, the examiner does not identify a suggestion or motivation found in the '483 patent to modify the teachings of '483. Applicants therefore respectfully request that the rejection of independent claims 23, 43, 45, and 50, and of dependent claims 24-25, 28-42,

44, 46-49, and 51-55 under 35 U.S.C. 103(a) over U.S. Patent No. 6,110,483 to Whitbourne et al. be withdrawn.

With respect to claims 41 and 42, the examiner states that "[i]t would be well within the limits of ordinary skill in the art to determine the optimal component ranges operation for the polymer coating giving the general conditions of the specification." As presented in the July 15, 2005 Amendment, Table V of the written description illustrates that the release rate characteristics of a polymer formulation are dependent on the proportion of hydrophilic to hydrophobic polymer. Moreover, a device coated with the particular polymers and polymer blends, such as a blend of hydrophobic and hydrophilic polymers as claimed in claims 36-42 of the instant application is not a routine variant, and thus would not be obvious to one of ordinary skill in the art.

**Rejections under 35 U.S.C. § 103 over U.S. Patent No. 6,110,483 to Whitbourne et al. and U.S. Patent No. 6,335,029 to Kamath et al.**

Claims 26-27 and 53-55 stand rejected under 35 U.S.C. §103(a) as being unpatentable over the combined disclosures of U.S. Patent No. 6,110,483 to Whitbourne et al. and U.S. Patent No. 6,335,029 to Kamath et al. (hereinafter '029), as indicated in item 8 on page 4 of the Office action of January 6, 2005. The examiner maintains that the '029 patent teaches a coil structure for a medical device, and that "[a] skilled artisan would have been motivated to continuously coat the coil as taught by '483". However, neither the '029 nor the '483 patent teaches a coating bridging between surfaces. Thus, the combination of the '029 and the '483 patents does not teach the limitations of independent claims 23, 43, 45, 50 or their dependent claims regarding "said coating ... bridging from one edge or surface to another...". Accordingly, the rejection of the dependent claims 26-27 and 53-55 cannot stand. Further, the examiner does not identify any suggestion or motivation in the '029 or the '483 patent to combine them or to modify their teachings to teach a device in which a coating bridges from one adjacent edge or surface to another.

In addition, '029 teaches the gas plasma deposition of a polymer barrier layer onto a medical device. The energy associated with gas plasma treatment could act to disrupt the structure of a

coating that bridges. Thus, '029 teaches away from independent claims 23, 43, 45, and 50 of the present invention, and teaches away from the dependent claims.

Applicants therefore respectfully request that the rejection of the claims 26-27 and 53-55 under 35 U.S.C. 103(a) over U.S. Patent No. 6,110,483 to Whitbourne et al. and U.S. Patent No. 6,335,029 to Kamath et al. be withdrawn.

Furthermore, there are additional reasons why several dependent claims are patentable. For example, neither the '438 nor the '029 patent teaches the limitation of claim 56, newly presented in this Amendment, that the scaffold has "a shape selected from the group consisting of mandrels, beads, egg-shapes, spheres, and threads".

Neither the '438 nor the '029 patent mentions the range of diffusion achieved by the medicated device. For example, these patents neither teach the limitation of claim 30 of the instant application that "when said device is implanted in a tissue, a therapeutic amount of said therapeutic agent diffuses at least about one centimeter from said device", nor the limitation of claim 31 that "in a zone of inhibition test, effective amounts of the therapeutic agent diffuse at least about one half centimeter from said device", nor the limitation of claim 45 that "a therapeutic amount of said therapeutic agent diffuses into the tissue at least about one centimeter from said device". The prior art devices and coatings do not teach such characteristics.

Also, neither reference teaches the classes of therapeutic agent mentioned in claims 57-58 or the therapeutic agents mentioned in claims 59-60. In summary, at least claims 30-31, 45, and 56-60 are patentable for additional reasons beyond those applicable to the independent claim from which they depend. Because of the reasons presented above, claims 23-60 are all patentable over U.S. Patent No. 6,110,483 to Whitbourne et al. and over the combination of '483 and U.S. Patent No. 6,335,029 to Kamath et al.

All of the stated grounds of rejection have been rendered moot. Applicants therefore respectfully request that the examiner reconsider all presently outstanding rejections and that they be withdrawn. Applicants believe that a full and complete reply has been made to the outstanding Office action and, as such, the present application is in condition for allowance.

Appl. No. 09/834,307  
Amendment dated July 1, 2005  
Reply to Office Action of January 6, 2005

If the examiner believes, for any reason, that personal communication will expedite prosecution of this application, the examiner is hereby invited to telephone the undersigned at the number provided.

A Notice of Allowance for claims 23-60 is respectfully requested.

Respectfully submitted,



Date: July 1, 2005

---

Michael A. Gollin  
Registration No. 31,957  
VENABLE LLP  
P.O. Box 34385  
Washington, D.C. 20043-9998  
Telephone: (202) 344-4000  
Direct Dial: (202) 344-4072  
Telefax: (202) 344-8300

DC2/620762v8

[Skip navigation](#)**MedlinePlus**

Trusted Health Information for You

A service of the U.S. NATIONAL LIBRARY OF MEDICINE  
and the NATIONAL INSTITUTES OF HEALTH **Search MedlinePlus**[About MedlinePlus](#) | [Site Map](#) | [FAQs](#) | [Contact Us](#)[Home](#) [Health Topics](#) [Drug Information](#) [Encyclopedia](#) [Dictionary](#) [News](#) [Directories](#) [Other Resources](#)[español](#)Other drug names: [A-Am](#) [An-Az](#) [B](#) [C-Ch](#) [Ci-Cz](#) [D-Dh](#) [Di-Dz](#) [E](#) [F](#) [G](#) [H](#) [I-J](#) [K-L](#) [M-Mh](#) [Mi-Mz](#) [N-Nh](#) [Ni-Nz](#) [O](#) [P-Pl](#) [Pm-Pz](#) [Q-R](#)  
[S-Sn](#) [So-Sz](#) [T-To](#) [Tp-Tz](#) [U-V](#) [W-Z](#) [0-9](#)

## Docetaxel

[Printer-friendly version](#)[E-mail to a friend](#)

(doe se tax' el)

Brand name(s): Taxotere

### Contents of this page:

- [About your treatment](#)
- [Precautions](#)
- [Side effects](#)
- [In case of emergency/overdose](#)

## IMPORTANT WARNING:

Docetaxel can cause a decrease in the number of blood cells in your bone marrow. Docetaxel also can cause liver damage. Tell your doctor if you have or have ever had liver disease. Your doctor will order certain lab tests to check your response to docetaxel. Allergic reactions may occur during docetaxel administration; you will receive medication before each treatment to help prevent these reactions. With these preventive medications, these allergic reactions are uncommon. Your health care provider will watch you carefully during the initial part of the infusion to treat these effects if they occur. If you experience any of the following symptoms, call your doctor immediately: shortness of breath, facial flushing, fever, chest pain, dizziness, lightheadedness, or skin rash.

## About your treatment

Your doctor has ordered the drug docetaxel to help treat your illness. The drug is given by injection into your vein.

This medication is used to treat:

- metastatic breast cancer

This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

Docetaxel is in a class of drugs known as taxanes; it slows or stops the growth of cancer cells in your body. The length of treatment depends on the types of drugs you are taking, how well your body responds to them, and the type of cancer you have.

## Precautions

Before taking docetaxel,

- tell your doctor and pharmacist if you are allergic to docetaxel or any other drugs.
- tell your doctor and pharmacist what prescription and nonprescription medications you are taking, especially aspirin, cyclosporine (Neoral, Sandimmune), erythromycin, ketoconazole (Nizoral), troleandomycin (TAO), and vitamins.

- tell your doctor if you have or have ever had liver or kidney disease.
- you should know that docetaxel may interfere with the normal menstrual cycle (period) in women and may stop sperm production in men. However, you should not assume that you cannot get pregnant or that you cannot get someone else pregnant. Women who are pregnant or breast-feeding should tell their doctors before they begin taking this drug. You should not plan to have children while receiving chemotherapy or for a while after treatments. (Talk to your doctor for further details.) Use a reliable method of birth control to prevent pregnancy. Docetaxel may harm the fetus.
- do not have any vaccinations (e.g., measles or flu shots) without talking to your doctor.

## Side effects

Side effects from docetaxel are common and include:

- thinned or brittle hair
- diarrhea
- loss of appetite
- nausea
- vomiting

Tell your doctor if either of these symptoms is severe or lasts for several hours:

- mouth blistering
- fatigue

If you experience any of the following symptoms or those listed in the IMPORTANT WARNING section, call your doctor immediately:

- unusual bruising or bleeding
- severe vomiting
- chills
- cough
- sore throat
- muscle aches, bone pain, and other flu-like symptoms
- difficulty swallowing
- change in normal bowel habits for more than 2 days
- swelling of the feet, increases in waistline size, weight gain, or overall puffiness

## In case of emergency/overdose

In case of overdose, call your local poison control center at 1-800-222-1222. If the victim has collapsed or is not breathing, call local emergency services at 911.

Last Revised - 04/01/2003



American Society of Health-System Pharmacists, Inc. Disclaimer

The MedMaster™ Patient Drug Information database provides information copyrighted by the American Society of Health-System Pharmacists, Inc., Bethesda, Maryland Copyright© 2004. All Rights Reserved.

[Home](#) | [Health Topics](#) | [Drug Information](#) | [Encyclopedia](#) | [Dictionary](#) | [News](#) | [Directories](#) | [Other Resources](#)

[Copyright](#) | [Privacy](#) | [Accessibility](#) | [Selection Guidelines](#)

U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894  
National Institutes of Health | Department of Health & Human Services

Page last updated: 19 May 2005

web sites

chemical info

market research

jobs

newsletters

List your site

Chemical: Bronopol



Powered by PubChem

Enter a chemical name, CAS Number, or molecular formula. Use \* for partial names (i.e. chloro\*)

**Synonyms:** Bronopol, 1,3-Propanediol, 2-bromo-2-nitro-, Bronocot, Onyxide 500, 2-Bromo-2-nitro-1,3-propanediol, 2-Bromo-2-nitropropane-1,3-diol, Bronosol, 2-Nitro-2-bromo-1,3-propanediol, 2-Bromo-2-nitropropan-1,3-diol, beta-Bromo-beta-nitrotrimethyleneglycol, Bronopolu, Bronotak, 2-Bromo-1-nitro-1,3-propanediol, Bioban BNPD-40, Bronidiol, Bronopol-boots, Broponol, Canguard 409, Lexgard bronopol, Myacide AS plus, Myacide S-1, S-2, NIST52-51-7, NISTC52517



click for details

Search for: Bronopol

IUPAC  
Name

2-bromo-2-nitro-propane-1,3-diol

CAS  
Number

52-51-7

Chemical  
Formula

C3H6BrNO4

Search web sites for Bronopol

DOW CORNING



## Featured Suppliers and resources for Bronopol (Ads) List your site here

## Linwood Chemical

Linwood chemical sells high quality dimethyl sulfoxide in ISO tank containers and drums from a dedicated ISO9001:2000 certified DMSO plant at reasonable prices. Linwood sources chemicals that are not readily available.

URL: <http://linwoodchem.com/> [Translate]

## Moto Chemistry Int'l Ltd.

Manufacturer

China

One of the most responsive specialty chemicals exporter & manufacturer in China. A leading supplier of pharmaceutical, biochemicals, dyestuff and agrochemical intermediates, ore chemicals and pigments.

URL: <http://www.motochem.com/> in English [Translate]Supplier  
CHINA  
chem service

## CCS CHEM

Industry service

China

Many reliable primary suppliers are available. CHINA CHEM SERVICE acts as a convenient and efficient assistant to help you do chem BIZ with china including sourcing, promoting, consulting, inspecting, sampling...

URL: <http://www.cnchemservice.com/> in English [Translate]Bohong  
Chemical  
International  
Co., Ltd.

## Bohong Chemical International Co., Ltd. Industry service

China

Based on long-term cooperation with many leading pharmaceutical manufacturers in China, we are prepared to execute customers highly specialized synthesis, the company devotes itself to the international trade of pharmaceuticals, chemical material and intermediate. Email: [info@bhchem.com](mailto:info@bhchem.com)

URL: <http://www.bhchem.com/> in English [Translate]

Find additional information about Bronopol at:

Chemical properties, names and structures

[PubChem](#)[NIST WebBook](#)[ChemIDplus](#)[MatWeb](#)

## Featured Suppliers (Ads)

**PERRYVIDE**  
USED CHEMICAL AND  
PHARMACEUTICAL  
PROCESS EQUIPMENT

CENTRIFUGES

GET IT NOW!  
GET IT FOR LESS!

Equipment Search

Supplier Of Used Equipment  
Chemical, Pharmaceutical,  
related Industries. Buyer  
Complete Plants, Lines  
Individual Pieces Of Equipm

MALVERN  
INSTRUMENTS

Malvern Instruments Ltd

FREE

TECHNICAL  
PUBLICATIONS

Free Magazines

Chemical  
Drawing  
Software

Chemistry Software Store

## Popular Chemicals

A B C D E F G H I J K L  
O P Q R S T U V W X

## Popular searches

## Resources

[ChemWeb - chemistry portal](#)[Chemistry jobs](#)[The Alchemist](#)



[ChemExper](#)

[WCI Database](#)

[SDBS](#)

[Merck ChemDat](#)

**Safety and toxicology data**

[ToxNet](#)

[ChemFate](#)

[Vermont SIRI](#)

[Cornell University](#)

[Oxford University](#)

**Chemistry dictionary**

[Acronyms Database](#)

**Literature**

[Wiley InterScience](#)

[ScienceDirect](#)

[ACS publications](#)

[Ingenta](#)

[Scirus](#)

**Patents**

[United States Patent and Trademark Office](#)

[The European Patent Office](#)

[Japan Patent Office](#)

**Recommend** ChemIndustry.com to your friends.

---

[Home](#) | [Advertising](#) | [Job Opportunities](#) | [Newsletter](#) | [Manage Account](#)  
[Privacy Policy](#) | [Terms](#) | [Contact Us](#)

(c) 1999-2003 ChemIndustry.com, Inc. • All Rights Reserved

## Vantocil

Poly (hexamethylene biguanide) hydrochloride (PHMB), the active ingredient in our VANTOCIL antimicrobial range is a fast-acting and broad spectrum bactericide with a wide formulation latitude. Consequently, by selection of appropriate co-formulants, a wide range of professional and domestic products can be formulated which meet the stringent demands of today's disinfection and hygiene industries.

### VANTOCIL antimicrobials can be used to formulate a wide variety of applications including:

- Professional disinfection
  - Liquid hard surface disinfectants for surfaces and floors
  - Solid disinfection tablets (slow release and effervescent)
  - Water cooling towers
  - Tunnel pasteurisers
  - Room fogging
  - Disinfectants for medical devices and equipment
- Household products
  - Antimicrobial dish washing liquids
  - Antimicrobial fabric conditioners
- Sanitizing wet wipes (for surfaces and hands)
- Antimicrobial hand soaps

### The primary performance benefits of PHMB include:

- Fast-acting and broad spectrum antimicrobial activity
- No cross-resistance with therapeutic antibiotics
- High level of retained biocidal activity in both soft and hard water conditions, and in the presence of organic load (BSA, yeast extract, milk and sucrose)
- Stable and effective performance over a pH range of 1-11
- Low surface activity and consequently can be readily water rinsed from surfaces and provide very low foaming products for Clean-In-Place applications

Through its longstanding familiarity with PHMB, Arch Biocides is well placed to offer formulation guidance and application advice in selecting the most appropriate co-formulants to ensure that your antimicrobial product offers the performance you would expect.

Whatever the end-use, Arch Biocides will ensure that our VANTOCIL antimicrobials do the right job for

### [Request Literature](#)

---

[Home](#) | [About Us](#) | [Products](#) | [Technical Support](#) | [Request Literature](#) | [Chemistry One on One](#) | [Contact Us](#) | [Site Map](#)

[Adhesives & Carpeting](#) | [Architectural Paints & Coatings](#) | [Marine Antifouling Paints](#)  
[Metalworking Fluids](#) | [Personal Care](#) | [Polymers](#)

Copyright© 2005 Arch Chemicals, Inc. All Rights Reserved.  
Your Access to this web site signifies your consent to our agreement

OMADINE®, OMACIDE®, TRIADINE®, and WAYHIB®  
are registered trademarks of Arch Chemicals, Inc.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**